Cardiovascular Diseases

Recently, the US FDA has approved a new drug therapy to treat adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. Ofev (nintedanib) capsules, the drug developed by Boehringer Ingelheim Pharmaceuticals, has shown efficacy in slowing down the rate of decline in pulmonary function in systemic sclerosis patient pool. Most of the systemic sclerosis patients suffer fatal death because of the loss of pulmonary function due to the lack of enough oxygen to the heart. Ofev is an oral triple angiokinase inhibitor, which simultaneously inhibits vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived g...